186 related articles for article (PubMed ID: 18570610)
21. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.
Chapple C; Van Kerrebroeck P; Tubaro A; Haag-Molkenteller C; Forst HT; Massow U; Wang J; Brodsky M
Eur Urol; 2007 Oct; 52(4):1204-12. PubMed ID: 17651893
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
[TBL] [Abstract][Full Text] [Related]
23. Review of fesoterodine.
Vella M; Cardozo L
Expert Opin Drug Saf; 2011 Sep; 10(5):805-8. PubMed ID: 21639817
[TBL] [Abstract][Full Text] [Related]
24. Fesoterodine in randomised clinical trials: an updated systematic clinical review of efficacy and safety.
Dell'Utri C; Digesu GA; Bhide A; Khullar V
Int Urogynecol J; 2012 Oct; 23(10):1337-44. PubMed ID: 22411206
[TBL] [Abstract][Full Text] [Related]
25. The concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal women.
Chughtai B; Forde JC; Buck J; Asfaw T; Lee R; Te AE; Kaplan SA
Post Reprod Health; 2016 Mar; 22(1):34-40. PubMed ID: 26883688
[TBL] [Abstract][Full Text] [Related]
26. Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies.
Kelleher CJ; Dmochowski RR; Berriman S; Kopp ZS; Carlsson M
BJU Int; 2012 Aug; 110(3):392-400. PubMed ID: 22129365
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms.
Grenabo L; Herschorn S; Kaplan SA; Cardozo L; Scholfield D; Arumi D; Carlsson M; Chapman D; Ntanios F
Curr Med Res Opin; 2017 Oct; 33(10):1731-1736. PubMed ID: 28758802
[TBL] [Abstract][Full Text] [Related]
28. Impact of fesoterodine on quality of life: pooled data from two randomized trials.
Kelleher CJ; Tubaro A; Wang JT; Kopp Z
BJU Int; 2008 Jul; 102(1):56-61. PubMed ID: 18564231
[TBL] [Abstract][Full Text] [Related]
29. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
30. A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older.
Wagg A; Arumi D; Herschorn S; Angulo Cuesta J; Haab F; Ntanios F; Carlsson M; Oelke M
Age Ageing; 2017 Jul; 46(4):620-626. PubMed ID: 28057620
[TBL] [Abstract][Full Text] [Related]
31. Flexible dose fesoterodine in the treatment of overactive bladder (OAB).
Tubaro A; De Nunzio C
BJU Int; 2013 Aug; 112(3):281-2. PubMed ID: 23826839
[No Abstract] [Full Text] [Related]
32. Efficacy and safety of fesoterodine treatment for overactive bladder symptoms in elderly women with and without hypertension.
Yokoyama O; Yamagami H; Hiro S; Hotta S; Yoshida M
Int J Urol; 2018 Mar; 25(3):251-257. PubMed ID: 29224251
[TBL] [Abstract][Full Text] [Related]
33. Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson's disease.
Yonguc T; Sefik E; Inci I; Kusbeci OY; Celik S; Aydın ME; Polat S
World J Urol; 2020 Aug; 38(8):2013-2019. PubMed ID: 31642953
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of fesoterodine fumarate in patients with overactive bladder: results of a post-marketing surveillance study in Korea.
Kim TH; Lee SE; Lee HE; Lee KS
Curr Med Res Opin; 2016 Aug; 32(8):1361-6. PubMed ID: 27046653
[TBL] [Abstract][Full Text] [Related]
35. Does fesoterodine have a role in the treatment of poorly managed patients with overactive bladder?
Morris V; Wagg A
Drug Des Devel Ther; 2014; 8():113-9. PubMed ID: 24470751
[TBL] [Abstract][Full Text] [Related]
36. Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trial.
Wagg A; Khullar V; Michel MC; Oelke M; Darekar A; Bitoun CE
Neurourol Urodyn; 2014 Jan; 33(1):106-14. PubMed ID: 23460503
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder.
Kraus SR; Ruiz-Cerdá JL; Martire D; Wang JT; Wagg AS
Urology; 2010 Dec; 76(6):1350-7. PubMed ID: 20974482
[TBL] [Abstract][Full Text] [Related]
38. [New perspectives of treatment with fesoterodine fumarate in patients with overactive bladder].
García-Baquero R; Madurga B; García MV; Fernández MA; Rosety JM; Álvarez-Ossorio JL
Actas Urol Esp; 2013 Feb; 37(2):83-91. PubMed ID: 23374672
[TBL] [Abstract][Full Text] [Related]
39. Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients.
Wagg A; Oelke M; Angulo JC; Scholfield D; Arumi D
Drugs Aging; 2015 Feb; 32(2):103-25. PubMed ID: 25673122
[TBL] [Abstract][Full Text] [Related]
40. Adherence to fesoterodine in women with overactive bladder in routine clinical practice.
Simó M; Porta O; Pubill J; Castillo MT; Mora I; Huguet E; Ortega JA; Martínez E
Actas Urol Esp; 2015 May; 39(4):222-8. PubMed ID: 25442908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
